AI diet coach takes on fatty liver: 216-Person trial launches

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Male or female aged 18 years or older; * Body mass index (BMI) between 25.0 and 45.0 kg/m² (including limit values); * Stable body weight for at least 3 months prior to inclusion (weight gain or loss \< 3%); * Medical history supporting the diagnosis of Non-alcoholic Fatty Liver Disease diagnosis (including available biology, imaging and/or histology data from the medical file); * Presence of significant liver steatosis attested by Fibroscan® Controlled Attenuation Parameter (CAP) value \> 300 dB/m; * Absence of severe fibrosis attested by Fibroscan Vibration controlled Transient Elastography (VTE) value \< 8.5 kPa (corresponding to stage F0-F2); * Availability of a WIFI internet connection at patient home * Able to provide written informed consent and agree to comply with the study protocol; * Covered by a French National Health Insurance plan Exclusion criteria: * History of liver disease other than NAFLD; * History of cirrhosis and/or liver cancer; * History of alcohol abuse and/or significant consumption in the past six months; * AST or ALT \> 5 times the upper limit of normal; * History of diabetes mellitus with another etiological diagnosis than type 2 diabetes; * Type 2 diabetes with HbA1c ≥ 8% and/or requiring insulin therapy; * Type 2 diabetes with significant change in oral antidiabetic therapy in the last 3 months; * Type 2 diabetes with significant change in GLP-1RA therapy in the last 6 months; * History of bariatric surgery or bariatric surgery planned during the study period; * Use of medications affecting weight or energy intake/expenditure in the last 3 months, including weight loss medications, corticosteroids, antipsychotic drugs or other medications according to investigator's opinion; * History of hypothyroidism with abnormal TSH value and/or adjustment of hormonal therapy in the last 3 months; * Severe chronic renal failure (eGFR\<30 ml/min/1.73 m2); * Severe cardiovascular disease, heart failure or any other medical condition not compatible with participation in the study according to investigator's opinion; * History of malignant tumor, unless considered to be in remission for 5 years or more; * Pregnant women or women planning to become pregnant; * Contra-indication to MRI examination or condition not allowing MRI to be carried out; * Persons participating in another research including a period of exclusion still in course * Patients who are unwilling or unable to give informed consent * Persons placed under judicial protection